Journal Watch · Frontiers in Immunology · 2026

Immunogenicity and safety of co-administered <i>Escherichia coli</i>-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.

Most adverse reactions were Grade 1, and no vaccine-related serious adverse events (SAEs) occurred.<h4>Conclusion</h4>Co-administration of HPV vaccine and HEV vaccine elicited high seroconversion rates and met non-inferiority criteria compared to administration of each vaccine alone, with a similar safety profile, supporting the feasibility of concomitant vaccination.

Yan R, Cen M, Zhou Y et al.Frontiers in Immunology4 min readPharma relevance 75/100

DOI: 10.3389/fimmu.2026.1837539PMID: 42292449Study type: randomised / controlled clinical trial

TL;DR

Most adverse reactions were Grade 1, and no vaccine-related serious adverse events (SAEs) occurred.<h4>Conclusion</h4>Co-administration of HPV vaccine and HEV vaccine elicited high seroconversion rates and met non-inferiority criteria compared to administration of each vaccine alone, with a similar safety profile, supporting the feasibility of concomitant vaccination.

Key findings

  • HPV-alone) was 0.78 (95% CI 0.64-0.96), based on concentrations of 318.30 and 407.54 IU/mL, respectively.
  • HEV GMCs were 10.51 WU/mL for the co-administration group and 11.18 WU/mL for the HEV-alone group (ratio 0.94; 95% CI 0.81-1.09).
  • All groups achieved 100% seroconversion.
  • Most adverse reactions were Grade 1, and no vaccine-related serious adverse events (SAEs) occurred.<h4>Conclusion</h4>Co-administration of HPV vaccine and HEV vaccine elicited high seroconversion rates and met non-inferiority criteria compared to administration of each vaccine alone, with a similar safety profile, supporting the feasibility of concomitant vaccination.

Numbers at a glance (from the abstract)

95%5%96.3%100%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Non-inferiority was met if the lower bound of the two-sided 95% CI for the seroconversion rate difference exceeded -5%, or that for the GMC ratio exceeded 0.5. Safety outcomes were assessed post-vaccination.<h4>Results</h4>Of the 480 women aged 18-25 years enrolled, 462 (96.3%) completed the full vaccination regimen and follow-up and were included in the per-protocol set (PPS), whereas all 480 participants (100%) were included in the safety set (SS). The GMC ratio for HPV-16 (HPV+HEV group vs. HPV-alone group) was 0.82 (95% CI 0.68-0.98), with corresponding GMCs of 433.16 IU/mL and 529.20 IU/mL, respectively. For HPV-18, the GMC ratio (HPV+HEV vs.

Full abstract (original)

Background: <h4>Background</h4>Human papillomavirus (HPV) and Hepatitis E virus (HEV) infections are major health concerns for women of reproductive age. Administration of HPV and HEV vaccines serves as primary prevention strategies. Our study aimed to demonstrate the immunogenicity and safety of co-administering <i>Escherichia coli</i>-produced bivalent HPV-16/18 vaccine and HEV vaccine compared to HPV-alone/HEV-alone.<h4>Methods</h4>This randomized, multicenter, open-label trial was conducted at 4 clinical study sites in Zhejiang Province, China. Participants were enrolled and randomly assigned into three groups to receive bivalent HPV vaccine co-administered with HEV vaccine, HPV vaccine alone and HEV vaccine alone following a 0, 1, 6-month vaccination schedule. The geometric mean concentrations (GMC) and seroconversion rates were measured at months 0 and 7 to evaluate immunogenicity.

What they did: Non-inferiority was met if the lower bound of the two-sided 95% CI for the seroconversion rate difference exceeded -5%, or that for the GMC ratio exceeded 0.5. Safety outcomes were assessed post-vaccination.<h4>Results</h4>Of the 480 women aged 18-25 years enrolled, 462 (96.3%) completed the full vaccination regimen and follow-up and were included in the per-protocol set (PPS), whereas all 480 participants (100%) were included in the safety set (SS). The GMC ratio for HPV-16 (HPV+HEV group vs. HPV-alone group) was 0.82 (95% CI 0.68-0.98), with corresponding GMCs of 433.16 IU/mL and 529.20 IU/mL, respectively. For HPV-18, the GMC ratio (HPV+HEV vs.

Results & conclusions: HPV-alone) was 0.78 (95% CI 0.64-0.96), based on concentrations of 318.30 and 407.54 IU/mL, respectively. HEV GMCs were 10.51 WU/mL for the co-administration group and 11.18 WU/mL for the HEV-alone group (ratio 0.94; 95% CI 0.81-1.09). All groups achieved 100% seroconversion. Most adverse reactions were Grade 1, and no vaccine-related serious adverse events (SAEs) occurred.<h4>Conclusion</h4>Co-administration of HPV vaccine and HEV vaccine elicited high seroconversion rates and met non-inferiority criteria compared to administration of each vaccine alone, with a similar safety profile, supporting the feasibility of concomitant vaccination.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1837539 · PubMed 42292449.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Most adverse reactions were Grade 1, and no vaccine-related serious adverse events (SAEs) occurred.<h4>Conclusion</h4>Co-administration of HPV vaccine and HEV vaccine elicited high seroconversion rates and met non-inferiority criteria compared to administration of each vaccine alone, with a similar safety profile, supporting the feasibility of concomitant vaccination.

What type of study is this?

It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Non-inferiority was met if the lower bound of the two-sided 95% CI for the seroconversion rate difference exceeded -5%, or that for the GMC ratio exceeded 0.5.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1837539. PubMed ID: 42292449. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yan R, Cen M, Zhou Y et al.. Immunogenicity and safety of co-administered &lt;i&gt;Escherichia coli&lt;/i&gt;-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1837539.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/immunogenicity-and-safety-of-co-administered-lt-i-gt-escherichia-coli-lt-837539/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides